Skip to content
OpenCapital
Get started

Inogen INGN Accrued Progress Collections and Price Adjustments

Accrued Progress Collections and Price Adjustments at other companies

ResMed logo
ResMedRMD
——

Other financials

Income statement

See full
Revenue$85.1M+3.4%
Gross profit$44.9M+1.7%
Operating income-$9.3M-21.9%
Net income-$8.3M-34.8%
EPS (diluted)-$0.30-20.0%

Balance sheet

See full
Cash & equivalents$93.1M-21.7%
Total debt$16.9M-11.9%
Total equity$182.9M-7.6%
Total assets$285.9M-7.3%

Cash flow

See full
Operating cash flow-$6.7M+60.2%
CapEx$210.0K-28.1%
Free cash flow-$6.9M+59.6%

Valuation

See full
Market cap$174.63M-9.7%
Enterprise value$98.45M-9.5%
P/S0.5×-0.1×

Profitability

See full
Gross margin52.8%-2.6pp
Operating margin-9.1%-0.8pp
Net margin-7.1%-0.8pp
FCF margin0.4%—

Returns & leverage

See full
Return on equity-13.1%-0.9pp
Debt / equity0.1×0.0×
Current ratio3.1×0.0×

Where this comes from

Reported directly by Inogen in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Inogen’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Inogen's accrued progress collections and price adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Inogen's accrued progress collections and price adjustments?
Inogen (INGN) reported accrued progress collections and price adjustments of $3.17M in Q1 2026.
How has Inogen's accrued progress collections and price adjustments changed year-over-year?
Inogen's accrued progress collections and price adjustments decreased by 37.9% year-over-year, from $5.11M to $3.17M.
What is the long-term trend for Inogen's accrued progress collections and price adjustments?
Over 5 years (2020 to 2025), Inogen's accrued progress collections and price adjustments has grown at a -21.2% compound annual growth rate (CAGR), from $11.82M to $3.6M.